Clinical Scorecard: Ependymomas in the Posterior Fossa: An In-Depth Analysis of Molecular Classification, Treatment Protocols, and Clinical Outcomes (Part I on Ependymomas in Various Locations)

At a Glance

Key Highlights

• Ependymomas represent approximately 5% of pediatric CNS tumors, with two-thirds in the posterior fossa.

• Molecular profiling has shifted WHO classification from histologic to integrated molecular entities.

• PFA tumors are linked to poorer outcomes and specific genomic alterations like 1q gain and/or 6q loss.

• Surgical management, particularly gross total resection (GTR), significantly influences survival outcomes.

• MRI is essential for diagnosis, surgical planning, and monitoring of ependymomas.

Guideline-Based Recommendations

Diagnosis

• MRI is the primary modality for assessing posterior fossa ependymomas.

Management

• Surgical resection is the central management strategy, with GTR preferred for better outcomes.

Monitoring & Follow-up

• Craniospinal MRI is indicated at diagnosis, during surveillance, and upon recurrence.

Risks

• Recurrent or refractory disease develops in nearly 45% of affected children.

Patient & Prescribing Data

Children with posterior fossa ependymomas.

GTR followed by immediate conformal radiotherapy shows improved survival compared to subtotal resection (STR).

Clinical Best Practices

• Consider molecular subgroup classification for prognostic assessment and treatment planning.

• Evaluate the need for second-look surgery in patients with residual tumor when safe.

Related Resources & Content

1. Acta Neuropathologica, Current Perspectives on the Clinical Approach to Intracranial Ependymoma and Its Unique Molecular Subtypes, 2016 -- https://link.springer.com/article/10.1007/s00401-016-1643-0

2. Acta Neuropathologica, EZHIP: Advancing Insights into Pediatric Posterior Fossa Ependymoma, 2021 -- https://link.springer.com/article/10.1007/s00401-021-02382-4

3. Acta Neuropathologica, Neurofibromatosis Type 2 Increases Risk for Ependymomas with Diverse Locations, Histological Features, and Molecular Characteristics, 2021 -- https://link.springer.com/article/10.1007/s00401-021-02304-4

4. Journal of Neuro-Oncology, Tailored Treatment Strategies for Pediatric Ependymomas with Relapse or Refractoriness: Insights from a Single Institution Study, 2025 -- https://link.springer.com/article/10.1007/s11060-025-05004-1

5. Childhood Ependymoma Treatment (PDQ®) - NCI -- https://www.cancer.gov/types/brain/hp/child-ependymoma-treatment-pdq

6. Current Perspectives on the Clinical Approach to Intracranial Ependymoma and Its Unique Molecular Subtypes

7. EZHIP: Advancing Insights into Pediatric Posterior Fossa Ependymoma

8. Neurofibromatosis Type 2 Increases Risk for Ependymomas with Diverse Locations, Histological Features, and Molecular Characteristics

9. Tailored Treatment Strategies for Pediatric Ependymomas with Relapse or Refractoriness: Insights from a Single Institution Study

10. Childhood Ependymoma Treatment (PDQ®) - NCI

11. cancers Review H3K27me3 Loss in Central Nervous Sy

12. cIMPACT‐NOW update 11: Proposal on adaptation of diagnostic criteria for IDH‐ and H3‐wildtype diffuse high‐grade gliomas and for posterior fossa ependymal tumors - PMC

13. European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence - ScienceDirect

14. European standard clinical practice recommendations for newly diagnosed ependymoma of childhood and adolescence

15. Phase 3 randomized trial of postirradiation chemotherapy in patients with newly diagnosed ependymoma: A report from the Children’s Oncology Group | Neuro-Oncology | Oxford Academic

16. ID #1021 Secondary analysis of outcome by treatment and age in ependymoma: A Report from the Children’s Oncology Group | Neuro-Oncology Pediatrics | Oxford Academic

17. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study - PMC